Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 19/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29174819 | 1.00 | PDE9A (0.43) | PDE9AHTR2AHTR2CHTR2BPDE1C | |
| SCHEMBL31051055 | 0.84 | PDE9A (0.44) | PDE9APDE1C | |
| SCHEMBL16981657 | 0.84 | PDE9A (0.44) | PDE9APDE1C | |
| SCHEMBL31051052 | 0.83 | ADORA3 (0.41) | — | |
| SCHEMBL30095946 | 0.78 | PDE2A (0.37) | — | |
| SCHEMBL30748213 | 0.77 | PDE9A (0.37) | PDE9APDE1C | |
| SCHEMBL29174802 | 0.77 | PDE9A (0.37) | PDE9APDE1C | |
| SCHEMBL30748211 | 0.77 | — | — | |
| SCHEMBL30095905 | 0.76 | KDM4E (0.44) | PDE9APDE1C | |
| SCHEMBL29174857 | 0.76 | KDM4E (0.44) | PDE9APDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4346806-A2 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | Biocryst Pharmaceuticals, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| CN-117529315-A | Imidazole-containing ALK2 kinase inhibitors | 生物水晶制药公司 | 2024-02-06 | — | — | CN | disclosed |
| WO-2022251188-A2 | IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASE | BIOCRYST PHARMACEUTICALS, INC. (US) | 2022-12-01 | — | — | WO | disclosed |